在患有安吉尔曼综合征的儿童中UBE3A-ATS反感性寡核酸rugonersen:一期1试验
Jörg F Hipp1, Carlos A Bacino2, Lynne M Bird3
1Roche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland. joerg.hipp@roche.com.
Nature medicine
|July 11, 2025
概括
鲁贡森是一种反感性寡核酸,通过部分正常化EEG异常和改善核心症状,对安吉尔曼综合征 (AS) 显示出前景. 这种针对遗传神经发育障碍的试验性治疗方法在第一阶段试验中证明了可接受的安全性.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学是一种遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 安吉尔曼综合征 (AS) 是一种严重的遗传神经发育障碍,没有经批准的疾病修饰治疗方法.
- AS是由UBE3A基因功能障碍引起的,影响神经元功能.
- 目前的管理重点是症状控制,缺乏疾病修饰疗法.
研究的目的:
- 评估rugonersen在患有AS的儿童中的安全性,耐受性和药理动力学.
- 探索rugonersen对AS相关的脑电图 (EEG) 异常和临床结果的潜在疗效.
主要方法:
- 一个第1期,多中心,开放标签,多重上升剂量试验 (TANGELO) 具有长期延长.
- 61名1至12岁的AS儿童接受了rugonersen.
- 探索性终点包括EEG三角功率和发育评估 (贝利尺度,Vineland尺度).
主要成果:
- 鲁戈纳森证明了可接受的安全性和耐受性概况,满足了主要终点.
- 观察到与AS相关的EEG异常的剂量依赖部分正常化.
- 核心AS领域的临床改善信号超过了自然历史的预期.
结论:
- 鲁戈纳森具有良好的安全性概况,并表明在安吉尔曼综合征中具有潜在的临床益处.
- 这些发现支持rugonersen继续发展为AS的新疗法.
- 需要进一步的研究来证实疗效和长期结果.
相关概念视频
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...